Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Global stocks fall on worries over EU stimulus details, coronavirus drug

Published 04/23/2020, 08:07 PM
Updated 04/24/2020, 07:35 AM
© Reuters. Pedestrian wearing a face mask walks near an overpass with an electronic board showing stock information in Shanghai

By Tom Arnold

LONDON (Reuters) - Global shares fell on Friday, hit by delays to an agreement on divisive details of the European Union's stimulus package and doubts about progress in the development of drugs to treat COVID-19.

MSCI's All Country World Index, which tracks stocks across 49 countries, was down 0.3% and heading for its worst week in three, while MSCI's broadest index of Asia-Pacific shares outside Japan fell 0.9%.

European stocks were 0.3% lower, with London's FTSE 100 shedding 0.6% as data showed UK retail sales crashed in March.

"It's a negative session," said François Savary, chief investment officer at Swiss wealth manager Prime Partners. "The market for the last week has been under consolidation after a strong rally. A lot of good news has already been priced in and news that the number of deaths had increased in the U.S. was also a warning sign for investors."

Avoiding another all-night bust-up, EU leaders agreed on Thursday to build a trillion euro emergency fund to help recover from the coronavirus pandemic, while leaving divisive details until the summer.

French President Emmanuel Macron said differences continued between EU governments over whether the fund should be transferring grant money, or simply making loans.

"The risk exists that a concrete decision on the creation of the recovery fund may not occur before September, thereby not being operational before early 2021," Goldman Sachs (NYSE:GS) European economist Alain Durre wrote in a note.

The banking index led the declines in European stocks after S&P cut Commerzbank (DE:CBKG)'s credit rating by a notch and lowered its outlook for Deutsche Bank (DE:DBKGn) to negative from stable.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

U.S. stock futures swung into positive territory, rising 0.6%. The S&P 500 and the Nasdaq turned negative at the close on Thursday in the wake of a report that Gilead Sciences Inc (NASDAQ:GILD)'s antiviral drug remdesivir had failed to help severely ill COVID-19 patients in its first clinical trial.

Gilead said the findings were inconclusive because the study conducted in China was terminated early.

The markets' sensitivity to news related to the medical treatment of COVID-19 reflected investors' desperation for a sign of when the global economy might start returning to normal, said Tim Ghriskey, chief investment strategist at New York-based wealth management firm Inverness Counsel.

"Any piece of bad news is likely to rattle the market," Ghriskey said. "Investors are keen for a semblance of hope that they can soon crawl out of their homes and get on with some form of normal life, even if with trepidation and fear."

U.S. coronavirus deaths exceeded 49,000 on Thursday, with the number of lives lost in April rising by an average of 2,000 a day, according to a Reuters tally.

Business activity in the world's largest economy plumbed record lows in April, mirroring dire figures from Europe and Asia as strict stay-at-home orders crushed production, supply chains and consumer spending, a survey showed.

The U.S. House of Representatives on Thursday passed a $484 billion bill to expand federal loans to small businesses and hospitals overwhelmed by patients.

President Donald Trump, who has indicated he will sign the bill, said late Thursday he may need to extend social distancing guidelines to early summer.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Oil prices broadly retained their recovery from a price collapse this week that pushed U.S. crude futures into negative territory for the first time ever, helped by producers such as Kuwait saying they would move to cut output.

Brent crude was up 18 cents, or 0.9%, at $21.51, after jumping 5% on Thursday. U.S. oil was steady at $16.50 a barrel, having surged 20% in the previous session.

But prices were headed for their third weekly loss and the outlook remains dim because global energy demand has evaporated due to business closures and travel curbs aimed at slowing the pandemic. In addition, some countries are running out of space to store the crude oil that they are not using.

EU leaders' agreement on the emergency fund helped lift Italian government bond yields. Short-dated Italian bond yields jumped 12 basis points. Italy's 10-year bond yield was up 7 bps at 2.08% and the closely-watched Italian/German 10-year bond yield gap was 14 bps wider from late Thursday levels at around 252 bps, erasing Thursday's narrowing.

The U.S. dollar gained as the euro fell 0.2% against the greenback to $1.07980 and 0.2% versus the yen at 116.17 yen.

Latest comments

Why need for drugs when vaccines are where the money is . Chloroquine works but is too cheap and is only for sick people , so lets prove it doesn't work , lol. Vaccines are good for everybody even healthy people , lol  you know what I mean .
The Independent, "citing research published in the Journal of the American Medical Association (JAMA), says that 88 percent. New York patients with coronavirus and treated with respirators have died. It tells me respirators  don't treat people , they make people more sick and tey die .Scientists note that over 30 percent. the subjects did not have elevated temperature when they were admitted to hospital and fever is one of the main symptoms of coronavirus. The Independent reports that as many as 94 percent of hospitalized patients had several comorbidities.
Test all and open the country. A vaccine or drug may be never found. We dont have any drug or vaccine for so many old deadly viruses.
Nice rise 😅
I was being sarcastic, BTW lol
Looks like the US brokerage houses want to repeat the US opening prices in Asian markets. The article fails to give credible reasons why Asia markets are 'poised to rise. -- Also, when an author places double opening brackets the reader expects follow-up closing brackets or ends up wasting their time.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.